logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

China East Air (00670) spent HK$10,900 to repurchase 4,000 shares on January 20th.

date
20:05 20/01/2025
avatar
GMT Eight
China Eastern Airlines Corporation Limited (00670) announced that it will spend HK$10,900 to repurchase...
CHINA EAST AIR (00670) announced on January 20, 2025, to repurchase 4000 shares at a cost of 10,900 Hong Kong dollars, with a repurchase price of 2.72 Hong Kong dollars per share. On the same day, they also spent 407,000 yuan to repurchase 100,000 A shares, with a repurchase price of 4.07 yuan per share.
Related Articles
HK Stock
DYNAM JAPAN (06889): Acquisition of an aircraft engine
HK Stock
CSTONE PHARMA-B(02616) announces that the IND for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) combination therapy has been approved in China, further exploring the potential of triple antibody treatment.
HK Stock
Decoding the core logic of medical data and AI, can RIMAG GROUP tell the story of Tempus AI in China well?
DYNAM JAPAN (06889): Acquisition of an aircraft engine
HK Stock
CSTONE PHARMA-B(02616) announces that the IND for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) combination therapy has been approved in China, further exploring the potential of triple antibody treatment.
HK Stock
Decoding the core logic of medical data and AI, can RIMAG GROUP tell the story of Tempus AI in China well?
HK Stock
RECOMMEND
Where the blockbuster weight-loss drug market stands today — and what’s coming next
Where the blockbuster weight-loss drug market stands today — and what’s coming next
icon
03/11/2025
Where the Nexperia auto-chip dispute stands as the U.S., China and EU move to contain the fallout
Where the Nexperia auto-chip dispute stands as the U.S., China and EU move to contain the fallout
icon
03/11/2025
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
icon
30/10/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.